Released Aug 7, 2025, after the close
10-Q filed Aug 7, 2025, 38 days after period end · 0001299130-25-000156
Q2 2025 · 10-Q
Revenue$39.77M$39.77M +10.4% vs Q2 2024+7.0% vs Q1 2025
Net Income-$41.93M-$41.93M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.14-$0.14 N/M vs Q2 2024N/M vs Q1 2025
Gross Profit$14,684,000+147.3%
Operating Income-$44,853,000N/M
Operating Cash Flowderived-$29,377,000N/M
Free Cash Flowderived-$29,927,000N/M
Margins · derived
Gross margin36.9%+20.4 pt vs Q2 2024
Operating margin-112.8%+375.5 pt vs Q2 2024
Net margin-105.4%+375.8 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $39.77M | $36.01M | $47.57M | $35.47M |
| Net Income | -$41.93M | -$173.32M | -$69.83M | -$71.39M |
| EPS Diluted | -$0.14 | -$0.64 | -$0.28 | -$0.32 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR